Cerevel Therapeutics Holdings Overview
Get informed when a big investor buys or sells
+ Follow-16.84
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Cerevel Therapeutics Holdings (CERE) currently reports a P/E ratio of -16.84. That is below the Healthcare sector average of 22.57. Use the charts on this page to explore Cerevel Therapeutics Holdings's P/E ratio history and peer comparisons.
Cerevel Therapeutics Holdings's P/E ratio of -16.84 is lower than the Healthcare sector average of 22.57. That is roughly 174.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Cerevel Therapeutics Holdings's market price to a fundamental measure such as earnings, sales, or book value. At -16.84, CERE can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -16.84, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.57. From there, open related valuation or income-statement pages for Cerevel Therapeutics Holdings, and consider following CERE for alerts when major investors trade the stock.
Cerevel Therapeutics Holdings is classified in the Healthcare sector. On P/E ratio, it currently shows -16.84 versus a sector average near 22.57. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CERE with unrelated industries.
